This page is part of the FHIR Specification (v1.4.0:
STU
3 Ballot 3). The current version which supercedes this version is
5.0.0
.
For
a
full
list
of
available
versions,
see
the
Directory
of
published
versions
. For a full list of available versions, see the
Directory of published versions 
This is the narrative for the resource. See also the
XML
or
or
JSON
format.
format. This example conforms to the
profile MedicationOrder
.
AC
followed
by
Paclitaxel
+
Trastuzumab
Course
1
AC followed by Paclitaxel + Trastuzumab Course 1
Name:
Cyclophosphamide
in
AC
(Doxorubicin
+
Cyclophosphamide)
Course:
1
Agent
Protocols
Options:
Name: Cyclophosphamide in AC (Doxorubicin + Cyclophosphamide)
Course: 1
Agent Protocols Options:
Cyclophosphamide
600
mg/m^2
IV
over
30
minutes
D1
Cyclophosphamide 600 mg/m^2 IV over 30 minutes D1
Offset:
None
Cycle
length:
Q21D
x
4
cycles
Usage
note:
every
effort
has
been
made
to
ensure
that
the
examples
are
correct
and
useful,
but
they
are
not
a
normative
part
of
the
specification.
©
HL7.org
2011+.
FHIR
DSTU2
(v1.0.2-7202)
generated
on
Sat,
Oct
24,
2015
07:43+1100.
Links:
Offset: None
Cycle length: Q21D x 4 cycles
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
© HL7.org 2011+. FHIR STU3 Candidate (v1.4.0-8139) generated on Thu, Mar 31, 2016 08:09+1100.
QA Page
Links:
Search
|
Version
History
|
Table
of
Contents
|
Compare
to
DSTU1
|
|
Version History
|
Table of Contents
|
Compare to DSTU2
|
|
Propose
a
change
|
Propose a change